Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic erosive inflammation in joints leading to the destruction of cartilage and bone.
Immunization of mice with type II collagen leads to the development of arthritis in the collagen-induced arthritis (CIA) model of RA. A number of anti-inflammatory compounds are effective in reducing inflammation in this model of arthritis.
This study was designed to establish a mouse model of RA and test the efficacy of the anti-inflammatory reference compound, Dexamethasone, in the CIA model of RA.
Average combined clinical score of all four paws. Clinical scores were assessed five days a week beginning on Day 27 and ending on Day 42.
Clinical Scoring Scale:
- No clinical signs; normal activity
- Hind or forepaw joint affected or minimal diffuse erythema/swelling
- Hind or forepaw joints affected or mild diffuse erythema/swellin
- Hind or forepaw joints affected or moderate diffuse erythema/swelling
- Marked diffuse erythema/swelling or digital joints affected
- Severe diffuse erythema/swelling of the entire paw, unable to flex digits
Based on the clinical score system, vehicle treated mice displayed an increase in inflammation severity throughout the course of the study. The Dexamethasone treated mice displayed a significant decrease in inflammation following drug administration that continued throughout the dosing period of fourteen days when compared to vehicle treated mice. Dexamethasone is a potent corticosteroid and reversed RA symptoms. Untreated sham mice maintained a clinical score of 0 throughout the study. Data are mean ± SEM; ** = p<0.01 compared to vehicle (N=8).